Everyone wants to know whether weekly rapamycin can shrink visceral fat and boost healthspan, and the PEARL trial has an answer that may surprise you. After 48 weeks in healthy adults, the primary endpoint of visceral fat did not budge, yet safety looked comparable to placebo. Some secondary signals, including lean mass and pain in women on 10 mg and better well-being on 5 mg, hint at benefits. But those are subgroup and self-reported findings, the drug was compounded, and no one has shown that it extends human lifespan. Here is what the data supports and what it does not.
This page is available in
